Core Insights - Mindray Medical announced third-quarter revenue of 9.091 billion yuan, representing a year-on-year growth of 1.53% [1] - The company's net profit attributable to shareholders for the third quarter was 2.501 billion yuan, a decline of 18.69% [1] - For the first three quarters, the total revenue was 25.834 billion yuan, a decrease of 12.38% [1] - The net profit attributable to shareholders for the first three quarters was 7.57 billion yuan, down 28.83% [1]

证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-046 深圳迈瑞生物医疗电子股份有限公司 第八届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 具体内容详见公司同日刊载于巨潮资讯网（www.cninfo.com.cn）上的《2025年第三季 度报告》。 表决结果：同意票11票、反对票0票、弃权票0票。 2、审议通过《关于公司向银行申请综合授信额度的议案》 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）第八届董事会第十五次会议 于2025年10月28日上午10:10在公司会议室以现场加通讯表决相结合的方式召开，会议通知 于2025年10月25日以电子邮件等方式送达全体董事。 会议由公司董事长李西廷先生主持。本次会议应出席董事人数11人，实际出席董事人 数11人，其中董事徐航先生以通讯表决方式参会，董事吴昊先生因公务原因未能亲自出席 会议，授权委托董事郭艳美女士代为出席并行使表决权。本次会议的召集、召开符合《中 华人民共和国公司法》（以下简称"《公司法》"）和《深圳迈瑞生物医疗电子股份有限公 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-047 深圳迈瑞生物医疗电子股份有限公司 本次利润分配方案符合《公司法》《企业会计准则》、证监会《上市公司监管指引第3 号—上市公司现金分红》及《公司章程》等规定，充分考虑了公司2025年三季度盈利状况、 未来发展资金需求、所处行业特点以及公司利润分配政策、股东回报规划等综合因素，符 合公司和全体股东的利益，该利润分配方案合法、合规、合理。 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）于2025年10月28日召开第 八届董事会第十五次会议，审议通过了《关于2025年第三次中期利润分配方案的议案》。 本次利润分配方案在公司2024年年度股东大会决议授权范围内，经公司董事会审议通过后， 无需再次提交股东会审议。 二、利润分配方案的基本情况 为积极响应监管号召、提高股东回报，公司持续保持一年多次分红，结合监管规则， 以2024年经审计的未分配利润为基准，合理考虑当期利润情况实施中期分红。根据《中华 人民共和国公司法》（以下简称"《公司法》"）和《深圳迈瑞生物医疗电子股份有限公司章 程》（以下简称"《公司章程》"）的有关规定，当法定盈余公积金累计 ...

Group 1: Industry Overview - The aging population in China is leading to an increase in the incidence of cardiovascular diseases and neurodegenerative diseases, creating a rigid demand for medical devices [1] - The cardiovascular disease mortality rate is the highest among urban and rural residents in China, making it a significant public health issue and a large market for treatment [1] - The medical device industry is shifting from extensive development to specialization and innovation-driven growth [2] Group 2: Company Developments - KaiLi Medical is expanding its business into high-value medical device fields such as minimally invasive surgery and cardiovascular intervention, leveraging its existing technology in ultrasound and endoscopy [1][2] - The company is focusing on intravascular ultrasound (IVUS) in the cardiovascular intervention field, which provides precise imaging for coronary heart disease treatment [1] - Mindray Medical is also heavily investing in the cardiovascular field, acquiring control of Huatai Medical to quickly enter the high-value consumables market [2] Group 3: Market Dynamics - The market growth rate in the cardiovascular field is significantly higher than in other areas, driven by the aging population and low penetration of cardiovascular intervention surgeries [2] - Imported medical device brands have historically dominated the intravascular ultrasound market, but domestic brands are beginning to break this monopoly [1] - The upcoming China International Import Expo will showcase products related to Alzheimer's disease screening, indicating ongoing competition between domestic and foreign medical device manufacturers [2] Group 4: Alzheimer's Disease Challenge - Alzheimer's disease poses a severe public health challenge in China, with approximately 10 million patients, the highest globally, leading to significant family and societal burdens [3] - The diagnosis rate for Alzheimer's disease in China is very low, with many patients remaining undiagnosed, missing critical intervention opportunities [3] - Nuclear medicine imaging technologies like PET/CT are becoming increasingly important in diagnosing major diseases, although challenges such as high costs and public fear of nuclear technology remain [3]

迈瑞医疗公告，第三季度营收为90.91亿元，同比增长1.53%；净利润为25.01亿元，下降18.69%。前三 季度营收为258.34亿元，下降12.38%；净利润为75.7亿元，下降28.83%。 ...

深圳迈瑞生物医疗电子股份有限公司 2025 年第三季度报告 证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-045 深圳迈瑞生物医疗电子股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度财务会计报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 2025年第三季度报告 公司是否需追溯调整或重述以前年度会计数据 □是 否 单位：元 | 项目 | 本报告期金额 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | --- | | 非流动性资产处置损益（包括已计提资产 | 9,156,304.00 | 101,713,111.00 | | | 减值准备的冲销部分） | | | | | 计入当期损益的政府补助（与公司 ...

Core Viewpoint - Mindray Medical, a leading player in the medical device industry, has announced plans to issue H-shares and list on the Hong Kong Stock Exchange, marking a significant step in its internationalization strategy [1][7]. Company History - Mindray was founded in 1991 by three colleagues, Li Xiting, Xu Hang, and Cheng Ming, who aimed to fill the gap in China's high-end medical device market [2][3]. - The company initially developed a pulse oximeter with borrowed funds, marking the beginning of its journey in the medical device sector [3][4]. - Mindray became the first Chinese medical device company to list overseas, successfully going public on the New York Stock Exchange in 2006 [6]. Financial Milestones - Mindray's market capitalization peaked at $3.59 billion during its time on the NYSE, but it later faced challenges leading to its privatization in 2016 for approximately $3.3 billion [6][7]. - The company made a significant return to the public market in 2018 by listing on the Shenzhen Stock Exchange, raising nearly 6 billion yuan, which was the largest IPO on the ChiNext that year [7]. Recent Developments - Mindray's international business has shown growth, with a 5.39% increase in revenue from international operations, which now accounts for nearly 50% of total revenue [7]. - The company aims to increase its overseas revenue share to over 70% and has set a strategic goal to rank among the top ten global medical device companies by 2030 [7]. Founders' Wealth - The founders of Mindray hold significant stakes in the company, with Li Xiting and Xu Hang ranking among China's wealthiest individuals following the company's IPOs [8][9]. - The stock price of Mindray surged post-IPO, contributing to the substantial increase in the founders' net worth, with Li Xiting's wealth reaching approximately $21.5 billion in 2021 [8][9].

Core Insights - The Biotech Economy Index (970038) closed at 2298.38 points, up 0.92%, with a trading volume of 24.11 billion yuan and a turnover rate of 1.39% [1] - Among the index constituents, 27 stocks rose while 22 fell, with Tigermed leading the gainers at 11.09% and Kaili Medical leading the decliners at 11.39% [1] Index Performance - The Biotech Economy Index had a net inflow of 169 million yuan from institutional investors, while retail investors experienced a net outflow of approximately 79.92 million yuan [1][2] - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (13.81% weight, latest price 222.83 yuan, market cap 270.17 billion yuan) [1] - Changchun High-tech (5.41% weight, latest price 117.55 yuan, market cap 47.95 billion yuan) [1] - Kanglong Chemical (4.66% weight, latest price 34.05 yuan, market cap 60.55 billion yuan) [1] - Tigermed (4.23% weight, latest price 59.48 yuan, market cap 51.21 billion yuan) [1] - Other notable constituents include Deep Technology, Muyuan Foods, and Aimeike [1] Capital Flow Analysis - The capital flow details indicate that Deep Technology had a net inflow of 201 million yuan from institutional investors, while retail investors saw a significant outflow of 222 million yuan [2] - Kanglong Chemical and Tigermed also experienced net inflows from institutional investors, but faced outflows from retail investors [2] - Overall, the data suggests a mixed sentiment among different investor classes within the Biotech Economy Index [2]

Core Insights - The CSI Medical Index (399989) closed at 7501.54 points, up 1.01%, with a trading volume of 25.053 billion yuan and a turnover rate of 1.55% [1] - Among the index constituents, 27 stocks rose while 23 fell, with Tigermed leading the gainers at 11.09% and Kaili Medical leading the decliners at 11.39% [1] Index Performance - The CSI Medical Index saw a net inflow of 323 million yuan from institutional investors, while retail investors experienced a net outflow of approximately 95.38 million yuan [1][2] - The top ten constituents of the CSI Medical Index include: - WuXi AppTec (14.78% weight, 106.04 yuan, +2.00%) with a market cap of 316.398 billion yuan - Mindray Medical (8.91% weight, 222.83 yuan, -1.00%) with a market cap of 270.168 billion yuan - United Imaging Healthcare (8.15% weight, 146.56 yuan, +1.21%) with a market cap of 120.789 billion yuan - Other notable constituents include Aier Eye Hospital, Kanglong Chemical, and Tigermed [1] Capital Flow Analysis - The capital flow details indicate that: - WuXi AppTec had a net inflow of 172 million yuan from institutional investors, while retail investors saw a net outflow of approximately 77.985 million yuan [2] - Other companies like Sanbo Brain Science and Furuida also experienced significant net inflows from institutional investors, while retail investors generally faced outflows [2]

Investment Rating - The industry investment rating is "Outperform the Market" [1] Core Viewpoints - The report highlights significant development opportunities for the pharmaceutical industry, particularly in innovative drugs and medical devices, as outlined in the "14th Five-Year Plan" [1][3] - The government has introduced various supportive policies for innovative drugs, including expedited approval processes and inclusion in medical insurance, which are expected to enhance the growth of the sector [3][5] - The report emphasizes the importance of improving the medical insurance system and the potential for commercial insurance to supplement coverage for innovative drugs, which could create a positive feedback loop for drug payments [3][5] Summary by Relevant Sections Investment Suggestions - The report recommends focusing on opportunities related to innovative drugs and medical devices, specifically mentioning companies such as Heng Rui Medicine, Innovent Biologics, BeiGene, Mindray Medical, and United Imaging Healthcare [3] - In the vaccine sector, it suggests paying attention to Zhifei Biological Products, Kangtai Biological Products, and CanSino Biologics [3] - For medical services, it highlights potential investments in Aier Eye Hospital and Tongce Medical [3] Policy Support and Market Trends - The report notes that the government is committed to supporting the development of innovative drugs and medical devices, which are crucial for public health and the independence of the biopharmaceutical industry [5] - It mentions that the time from drug approval to inclusion in the medical insurance directory has significantly decreased, with approximately 80% of innovative drugs being included within two years of market launch [5] - The report also discusses the optimization of fertility support policies and the response to aging populations, indicating that these factors could benefit related industries, including vaccines and long-term care services [5]